Innovodigm (India’s first reported vaccine micro-array patch company) is developing a proprietary vaccine microarray patch (MAP) platform that combines precise microneedle engineering with a thermostability-oriented formulation/coating approach—enabling needle-free delivery, simplified logistics, reduced medical waste, and potential dose-sparing.By reducing reliance on cold-chain and simplifying administration, the platform directly supports India’s universal immunization priorities under the National Health Mission by addressing last-mile reachability and workforce constraints.Quantified impact (India + global):India reachability gap: WHO-UNICEF (WUENIC) reporting cited by UNICEF indicates ~2.7 million “zero-dose” children in India in 2021, improving to ~1.1 million in 2022—showing both the scale of the challenge and the impact of improved delivery systems.Child lives saved baseline: Immunization already averts an estimated ~4.4 million deaths globally each year; technologies that expand coverage and reduce drop-outs can meaningfully add to this impact over time.Cross-contamination / unsafe injection reduction: Eliminating needles and syringes d
Momentum is derived from funding recency, velocity, round count and scale.
Health and social work
Source: Ministry of Corporate Affairs company master (open data). Capital figures are as-of the 2021 registry snapshot, not live.
Extracted from Innovodigm Private Limited's own website, fetched Jul 2026. Verification badges reflect format/MX checks, not endorsement.